Followers | 10 |
Posts | 1850 |
Boards Moderated | 0 |
Alias Born | 06/02/2016 |
Sunday, January 01, 2017 7:45:27 PM
Looks to be more difficulty ahead for 2017 as the company struggles to stay afloat and will most likely need to continue dilution of shares at fractions of the current retail share price to make debt payments. It also appears as though the acquisitions are having some setbacks given the first acquisition announced as complete in an April 2016 pr still is not reflected in the financials through September 30 2016.
Below is the the 2016 3rd quarter dilution with zero revenue or assets added to the balance sheet.
Per TA on August 15 2016: (coverted to R/S totals)
Issued and outstanding is 1,182,439
Free trading (float) is 321,567
Per TA on 10/19
Issued and outstanding is 1,232,585
Free trading (float) is 371,590
In conclusion:
Issued and outstanding +50,146 shares or a +4% increase
Free Trading (float) +50,023 shares or a +15.5% increase
DILUTION
I
L
U
T
I
O
N
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM